Atjaunināt sīkdatņu piekrišanu

COVID-19 Pandemic: A Global High-Tech Challenge at the Interface of Science, Politics, and Illusions [Mīkstie vāki]

(Klausrose Consulting, Pediatric Drug Development and More; Riehen (Basel), Switzerland)
  • Formāts: Paperback / softback, 248 pages, height x width: 229x152 mm, weight: 400 g
  • Izdošanas datums: 09-Mar-2022
  • Izdevniecība: Academic Press Inc
  • ISBN-10: 0323991491
  • ISBN-13: 9780323991490
Citas grāmatas par šo tēmu:
  • Mīkstie vāki
  • Cena: 152,25 €
  • Grāmatu piegādes laiks ir 3-4 nedēļas, ja grāmata ir uz vietas izdevniecības noliktavā. Ja izdevējam nepieciešams publicēt jaunu tirāžu, grāmatas piegāde var aizkavēties.
  • Daudzums:
  • Ielikt grozā
  • Piegādes laiks - 4-6 nedēļas
  • Pievienot vēlmju sarakstam
COVID-19 Pandemic: A Global High-Tech Challenge at the Interface of Science, Politics, and IllusionsPalielināt
  • Formāts: Paperback / softback, 248 pages, height x width: 229x152 mm, weight: 400 g
  • Izdošanas datums: 09-Mar-2022
  • Izdevniecība: Academic Press Inc
  • ISBN-10: 0323991491
  • ISBN-13: 9780323991490
Citas grāmatas par šo tēmu:
Permanent link: https://www.kriso.lv/db/9780323991490.html
Keywords:

The COVID-19 Pandemic: A Global High-Tech Challenge at the Interface of Science, Politics, and Illusions discusses COVID-19 as the first pandemic in the Internet era and our current reality of continuous reports, news, and updates. Since its beginning, we were daily bombarded with news of what was happening around the world. There was no global political leadership. The United States was politically partially paralyzed. Russia and China hoped to gain diplomatic profile worldwide, but their vaccines are of limited efficacy, and trust in their clinical data is rightly low. The European Union did not order enough vaccines in time, but sued a large manufacturer for delivery delays. Now it is setting up yet another bureaucratic institution. At least the pharmaceutical or life science industry paved the way out, but is not enthusiastically praised for it. It would be too easy and superficial to blame mistakes of governments and leaders on stupidity. Idiocy exists, but we have to go deeper to understand how illusions and blind spots in today’s common perception and science, inertia, arrogance, conflicts of interest, competition of individuals, and states and institutions for public recognition have contributed to a multitude of flawed assessments and direct mistakes. Healthcare professionals and anyone interested in an in-depth understanding of humankind’s response to the COVID-19 challenge will not get around the key conclusions of this book.

  • Outlines key elements of modern civilization, public health, and drug and vaccine development on the background of the COVID-19 pandemic
  • Discusses the historical roots of separate drug approval of vaccines and drugs in administratively classified "children" (of whom many are bodily mature long before their 16th or 18th birthday), and why the belated approval of vaccines against COVID-19 in minors is not based on science, but on blurs and conflicts of interest
  • Outlines key elements we need to address to become better prepared for future global health challenges. In the first place, we do not need new institutions, but to overcome intellectual barriers and blind spots
Foreword xi
Preface xiii
1 Introduction
1 Introduction
1(12)
References
13(22)
2 We are no longer hunters and gatherers. Societies, states, values, and healthcare today
3 Development of drugs and vaccines
4 COVID-19-The disease
1 Introduction
35(1)
2 DNA and RNA
36(5)
3 Severe acute respirarory syndrome coronavirus 2 (SARS-CoV-2) and COVID-19 disease
41(2)
4 Modern society and public health
43(2)
5 Traditional avenues of prevention
45(2)
6 Vaccines
47(6)
7 Diagnostics
53(1)
8 Treatment
53(3)
9 COVID-19, children, and "children"
56(4)
10 COVID-19 variants
60(1)
11 Conclusions
61(1)
References
62(9)
5 Russian and Chinese vaccines
1 Russian vaccines
71(2)
2 Chinese vaccines
73(2)
3 Assessment
75(1)
References
76(3)
6 The European Union (EU) response to the COVID-19 pandemic
1 The original course of the pandemic in Europe
79(1)
2 Details of the EU response
80(1)
3 Future EU plans
81(2)
4 A preliminary assessment of the EU response to the COVID-19 pandemic
83(1)
References
83(2)
7 COVID-19 vaccines global access (COVAX) and more
1 Introduction
85(1)
2 Key international organizations
85(2)
3 COVID-19 vaccines global access (COVAX)
87(1)
4 The discussion about booster shots
87(1)
5 Preliminary COVAX assessment
88(1)
References
88(3)
8 International healthcare structures and COVID-19
1 WHO basics and "Public Health Emergencies of International Concern" (PHEICs)
91(1)
2 International Health regulations (IHR) and PHEICs
92(1)
3 The WHO's life of its own
93(3)
4 The WHO and progress in healthcare
96(3)
5 The WHO in the COVID-19 pandemic
99(2)
6 The independent panel for pandemic preparedness and response (IPPR) report
101(2)
7 Assessment of the WHO IPPR recommendations
103(1)
8 Conclusions
104(1)
References
105(4)
9 Low-tech and high-tech challenges. Accidents and disasters. Technical and scientific progress and its perception by science and the public
1 Introduction
109(1)
2 Groupthink
110(1)
3 US space shuttle disasters
111(2)
4 Boeing 737 MAX crashes
113(1)
5 Nuclear plant meltdown in Fukushima, Japan, after a tsunami
114(1)
6 Lead poisoning
115(4)
7 Love Canal/Blackcreek village
119(1)
8 Mercury poisoning
120(1)
9 Bhopal
121(1)
10 Tobacco smoking
121(2)
11 BSE and Jacob-Creutzfeld-disease
123(2)
12 Intermediate summary
125(1)
13 Discussion and conclusions
126(3)
References
129(12)
10 Basic research, applied research, and die real world
11 Conflicts of interest and the self-picture of medicine and scientists
1 Introduction
141(4)
2 Science is part of society
145(2)
3 The special edition on 150 years "Nature" in 2019
147(2)
4 The "Nature" coverage of the European Union (EU) science budget deliberations in 2019
149(2)
5 The term "medical-industrial complex" and its ramifications
151(2)
6 Conclusions
153(1)
References
154(5)
12 Vaccination hesitancy
1 Introduction
159(7)
2 Discussion
166(1)
3 Additional dimensions
167(1)
4 Conclusions
168(1)
References
169(2)
13 Social inequality, developing countries, and COVID-19
1 Introduction
171(3)
2 Social framework and the responsibility tor one's fate and health
174(2)
3 Social inequality: The sociology approach
176(1)
4 Ideologies and politics that promise(d) to abolish poverty
177(4)
5 Developing countries and the COVID-10 pandemic
181(2)
6 The misconception of a weakening of intellecmal property as a way out of the pandemic
183(3)
7 Conclusions
186(1)
References
186(3)
14 Politics, illusions, websites, and the real world
1 Humanity and communication
189(2)
2 Fairy tales, oral tradition, the worlds of radio and television, and the internet
191(1)
3 Politics, websites, and the real world
192(1)
4 The COVID-19 pandemic and the internet
193(2)
5 Conclusions
195(1)
References
195(2)
15 Global warming, Armageddon warnings, and the COVID-19 pandemic
1 Climate change and global warming: The basics
197(4)
2 The predicted effect of climate change on humans
201(1)
3 Global warming and the COVID-19 pandemic
201(4)
4 The mixing of geoscience, social, and medical challenges
205(1)
5 Scientific warnings in the past
205(3)
6 The privileges ot youth
208(1)
7 COVID-19 is a high-tech challenge
208(1)
References
209(17)
16 China and Russia are giants on feet of clay
17 Conclusions and outlook
1 Conclusions
226(2)
References
228(3)
Index 231
Dr. Klaus Rose is a medical doctor by training and profession. In the 1990s, after clinical training, he joined the pharmaceutical industry. In 1999 at Novartis in Switzerland, he came across clinical studies in children and was intrigued. His eldest daughter suffered from SturgeWeber syndrome, which is serious and very rare. Dr. Rose became passionate about pediatric drug development” and what the European Medicines Agency (EMA) called Better Medicines for Children.” He became global head pediatrics at Novartis from 20012005 and moved to the same position 20052009 at Genentech/Roche. After one more year at a regulatory company, he became an independent consultant in 2011. He advises companies on EMA pediatric investigation plans” (PIPs), and Food and Drug Administration (FDA) pediatric requests or demands. He detected fundamental flaws in Pediatric Drug Development and publishes about this (and more) in peer-reviewed journals and medical textbooks.